AGIO

Agios Pharmaceuticals, Inc.

42.55 USD
-0.04 (-0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Agios Pharmaceuticals, Inc. stock is up 28.2% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 4 CALLs, 6 PUTs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
29 May 13:55 21 Jun, 2024 25.00 CALL 50 305
30 May 13:48 21 Jun, 2024 25.00 CALL 50 355
30 May 16:07 19 Jul, 2024 35.00 PUT 200 247
31 May 14:36 21 Jun, 2024 35.00 PUT 1106 1956
31 May 14:36 21 Jun, 2024 35.00 PUT 295 1956
03 Jun 13:30 19 Jul, 2024 35.00 PUT 500 585
03 Jun 13:58 21 Jun, 2024 35.00 PUT 979 3308
03 Jun 14:08 21 Jun, 2024 35.00 PUT 1202 3308
03 Jun 17:37 15 Nov, 2024 50.00 CALL 136 2
13 Jun 17:24 19 Jul, 2024 40.00 CALL 50 520

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes. AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

  • Cantor Fitzgerald
    Mon Jun 17, 09:30
    buy
    confirm
  • JP Morgan
    Thu Jun 13, 17:06
    hold
    confirm
  • Goldman Sachs
    Tue Jun 4, 11:14
    hold
    confirm
  • RBC Capital
    Tue Jun 4, 09:30
    buy
    confirm